Drug intelligence / Profile preview

Yinqi Sanhuang Decoction

Development stage: Phase 3
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Yinqi Sanhuang Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is primarily indicated for the treatment of chronic hepatitis B and hepatitis B-related liver cirrhosis, including both compensated and decompensated stages. The decoction is designed for "detoxification" and has been evaluated in clinical studies for its ability to reduce the annual incidence of primary liver cancer (hepatocellular carcinoma) in patients with compensatory liver cirrhosis. Clinical data suggests that the use of this decoction can reduce the annual incidence of liver cancer in this population to approximately 1%. It is typically administered as an oral liquid preparation.

Other names: Yinqi Sanhuang TangYinqi Sanhuang Formula

Beyond the preview

Go deeper on Yinqi Sanhuang Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yinqi Sanhuang Decoction.